Funding for this research was provided by:
Stiftelsen Konung Gustaf V:s 80-årsfond (FAI-2014-0005)
Åke Wiberg Stiftelse (M17-0166)
Innovative Medicines Initiative (115142)
Received: 12 September 2019
Accepted: 3 December 2019
First Online: 27 December 2019
: All authors declare that there are no commercial or financial conflicts of interest in the context of this study. Karolinska Institutet has been a partner with UCB Pharma within the Innovative Medicines Initiative projects BTcure and RTCure, which are public–private partnership between the EU and the European Federation of Pharmaceutical Industries. The authors S. Rapecki and I. Melas are employees of UCB Pharma. The author L. Mathsson-Alm is an employee of Thermo Fisher Scientific.